An upper limit for macromolecular crowding effects

First Page		Document Content
Medical emergencies Aging-associated diseases Organ failure Nephrology Kidney diseases Acute coronary syndrome Reperfusion therapy Chronic kidney disease Percutaneous coronary intervention Medicine Health Cardiology		An upper limit for macromolecular crowding effects Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 1,02 MB Share Document on Facebook

	Appendix B: Inclusion and Exclusion Criteria Inclusion criteria Patients was 20 years old Patients suitable for percutaneous coronary intervention (PCI) DocID: 1t846 - View Document
	Microsoft Word - PMDA-S-薬剤溶出型冠動脈ステント-070715_EE.docx DocID: 1remo - View Document
	Opportunity for Human Research Subjects Cardiovascular Inflammation Reduction Trial (CIRT). A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of ca DocID: 1r6ms - View Document
	AHRQ Quality Indicators™ Inpatient Quality Indicators Assess the quality of care for adults in the hospital Inpatient Quality Indicators— DocID: 1r2Dz - View Document
	NIH Public Access Author Manuscript N Engl J Med. Author manuscript; available in PMC 2014 February 11. NIH-PA Author Manuscript DocID: 1qMu1 - View Document